Cognitive improvements linked to lysophosphatidylethanolamine after olanzapine treatment in drug-naïve first-episode schizophrenia.

IF 3.5 3区医学 Q2 ENDOCRINOLOGY & METABOLISM Metabolomics Pub Date : 2024-10-01 DOI:10.1007/s11306-024-02171-6

Juanhua Li, Yuanguang Xu, Xin Wang, Caixing Liu, Zezhi Li, Meihong Xiu, Hongying Chen

{"title":"Cognitive improvements linked to lysophosphatidylethanolamine after olanzapine treatment in drug-naïve first-episode schizophrenia.","authors":"Juanhua Li, Yuanguang Xu, Xin Wang, Caixing Liu, Zezhi Li, Meihong Xiu, Hongying Chen","doi":"10.1007/s11306-024-02171-6","DOIUrl":null,"url":null,"abstract":"Background: Cognitive impairments are a hallmark symptom of schizophrenia (SCZ). Phosphatidylethanolamine (PE) is the second most abundant phospholipid in mammalian cells, yet its role in cognitive deficits remains unexplored. The aim of this study was to investigate the association between plasma LysoPE and cognitive improvements following olanzapine monotherapy in drug-naïve first-episode (DNFE) SCZ patients.Methods: Twenty-five female DNFE SCZ patients were treated with olanzapine for four weeks, and cognitive function was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline and after the 4-week follow-up. Utilizing an untargeted ultra-performance liquid chromatography-mass spectrometry (UPLC-MS)-based metabolomics approach, we measured LysoPE concentrations.Results: Significant improvements in immediate and delayed memory domains were observed post-treatment. We identified nine differential LysoPE species after olanzapine monotherapy, with increased concentrations for all LysoPE except LysoPE (22:6). Elevated LysoPE (22:1) concentration positively correlated with cognitive improvement in patients. Baseline LysoPE (16:1) emerged as a predictive factor for cognitive improvement following olanzapine monotherapy.Conclusions: This study offers preliminary evidence for the involvement of LysoPE in cognitive improvements observed in drug-naïve first-episode SCZ patients after olanzapine treatment.","PeriodicalId":18506,"journal":{"name":"Metabolomics","volume":"20 5","pages":"108"},"PeriodicalIF":3.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11306-024-02171-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cognitive impairments are a hallmark symptom of schizophrenia (SCZ). Phosphatidylethanolamine (PE) is the second most abundant phospholipid in mammalian cells, yet its role in cognitive deficits remains unexplored. The aim of this study was to investigate the association between plasma LysoPE and cognitive improvements following olanzapine monotherapy in drug-naïve first-episode (DNFE) SCZ patients.

Methods: Twenty-five female DNFE SCZ patients were treated with olanzapine for four weeks, and cognitive function was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) at baseline and after the 4-week follow-up. Utilizing an untargeted ultra-performance liquid chromatography-mass spectrometry (UPLC-MS)-based metabolomics approach, we measured LysoPE concentrations.

Results: Significant improvements in immediate and delayed memory domains were observed post-treatment. We identified nine differential LysoPE species after olanzapine monotherapy, with increased concentrations for all LysoPE except LysoPE (22:6). Elevated LysoPE (22:1) concentration positively correlated with cognitive improvement in patients. Baseline LysoPE (16:1) emerged as a predictive factor for cognitive improvement following olanzapine monotherapy.

Conclusions: This study offers preliminary evidence for the involvement of LysoPE in cognitive improvements observed in drug-naïve first-episode SCZ patients after olanzapine treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对初次发病的精神分裂症患者进行奥氮平治疗后，认知能力的改善与溶血磷脂酰乙醇胺有关。

背景：认知障碍是精神分裂症（SCZ）的标志性症状。磷脂酰乙醇胺（PE）是哺乳动物细胞中含量第二高的磷脂，但它在认知障碍中的作用仍未得到研究。本研究旨在探讨血浆溶血磷脂酰乙醇胺（LysoPE）与药物治疗无效的首次发病（DNFE）SCZ患者接受奥氮平单药治疗后认知能力改善之间的关系：25名女性DNFE SCZ患者接受了为期四周的奥氮平治疗，并在基线和四周随访后使用神经心理状态评估可重复电池（RBANS）对认知功能进行了评估。我们采用基于非靶向超高效液相色谱-质谱联用仪（UPLC-MS）的代谢组学方法测量了LysoPE的浓度：结果：治疗后，即时记忆和延迟记忆领域均有显著改善。在奥氮平单药治疗后，我们发现了九种不同的 LysoPE，除了 LysoPE (22:6)，其他 LysoPE 的浓度都有所增加。LysoPE（22:1）浓度的升高与患者认知能力的改善呈正相关。基线 LysoPE（16:1）是奥氮平单药治疗后认知改善的预测因素：本研究提供了初步证据，证明LysoPE参与了药物无效的首发SCZ患者在接受奥氮平治疗后认知能力的改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Metabolomics 医学-内分泌学与代谢

CiteScore

6.60

自引率

2.80%

发文量

审稿时长

2 months

期刊介绍： Metabolomics publishes current research regarding the development of technology platforms for metabolomics. This includes, but is not limited to: metabolomic applications within man, including pre-clinical and clinical pharmacometabolomics for precision medicine metabolic profiling and fingerprinting metabolite target analysis metabolomic applications within animals, plants and microbes transcriptomics and proteomics in systems biology Metabolomics is an indispensable platform for researchers using new post-genomics approaches, to discover networks and interactions between metabolites, pharmaceuticals, SNPs, proteins and more. Its articles go beyond the genome and metabolome, by including original clinical study material together with big data from new emerging technologies.